Rotavirus vaccines.
Encouraging results have been reported from several large trials of tetravalent rhesus rotavirus vaccine, with efficacy of 70-80% against severe disease. A recent Venezuelan study showed similar results to trials in USA and Europe. The vaccine may soon be licensed in USA. It provides the exciting prospect of a strategy to prevent one of the world's major child killers. Other candidate vaccines are under development including human-bovine reassortants, neonatal strains, non-replicating rotaviruses, vector vaccines and other genetically engineered products. Second and third generation rotavirus vaccines are on the horizon. The need for a rotavirus vaccine is well accepted by paediatricians, but public health authorities need to be lobbied. Other issues which need to be addressed include relative importance of non-group A rotaviruses, possible administration with OPV, the influence of breast feeding, and most importantly, cost. It is essential that rotavirus vaccine is somehow made available to all of the world's children, not just those in developed countries.
Barnes
G
G
Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville, Victoria, Melbourne, Australia.
D002675:Child, Preschool; D003967:Diarrhea / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D012401:Rotavirus / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D014765:Viral Vaccines